Intravenous levodopa administration in humans based on a two-compartment kinetic model

Journal of Neuroscience Methods

Volumn 159, Issue 2, 2007, Pages 300-307

  Gordon, Mollie ^a   Markham, Joanne ^a   Hartlein, Johanna M ^a   Koller, Jonathan M ^a   Loftin, Susan ^a   Black, Kevin J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbidopa; Chromatography; Growth hormone; Human; Intravenous; Levodopa pharmacokinetics; Parkinson disease; Prolactin; Tourette syndrome

Indexed keywords

CARBIDOPA; GROWTH HORMONE; LEVODOPA; PLACEBO; PROLACTIN;

ADULT; ANXIETY DISORDER; APPETITE; ARTICLE; CLINICAL TRIAL; COLD; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISTRACTIBILITY; DIZZINESS; DRUG BLOOD LEVEL; FATIGUE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; KINETICS; LINGUISTICS; LISTLESSNESS; MALE; MENTAL CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; WELLBEING; XEROSTOMIA; YAWNING;

ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANTIPARKINSON AGENTS; BODY FLUID COMPARTMENTS; CARBIDOPA; DOPAMINE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; LEVODOPA; MALE; MODELS, BIOLOGICAL; PAIN MEASUREMENT; PROLACTIN;

EID: 33845427430     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2006.07.010     Document Type: Article

References (50)

1. Birkmayer W., and Hornykiewicz O. Der l-3,4-dioxyphenylalanin (=DOPA)-Effekt bei Parkinson-Akinese. Wien Klin Wochenschr 73 (1961) 787-788
2. Black K.J., and Mink J.W. Response to levodopa challenge in Tourette syndrome. Movement Disord 15 (2000) 1194-1198
3. Black K.J., Hershey T., Gado M.H., and Perlmutter J.S. Dopamine D1 agonist activates temporal lobe structures in primates. J Neurophysiol 84 (2000) 549-557
4. Black K.J., Hershey T., Koller J.M., Carl J.L., and Perlmutter J.S. Mapping and quantification of dopamine D2 receptor activation. J Neuropsychiatr Clin Neurosci 14 (2002) 118-119
5. Black K.J., Hershey T., Koller J.M., Videen T.O., Mintun M.A., Price J.L., et al. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci USA 99 (2002) 17113-17118
6. Black K.J., Carl J.L., Hartlein J.M., Warren S.L., Hershey T., and Perlmutter J.S. Rapid intravenous loading of levodopa for human research: clinical results. J Neurosci Meth 127 (2003) 19-29
7. Brannan T., Prikhojan A., and Yahr M.D. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation. Brain Res 784 (1998) 148-153
8. Carlsson A., Lindqvist M., Magnusson T., and Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 127 (1958) 471
9. Chan P.L., Nutt J.G., and Holford N.H. Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn 31 (2004) 243-268
10. Chan P.L.S., Nutt J.G., and Holford N.H.G. Importance of within subject variation in levodopa pharmacokinetics: a 4-year cohort study in Parkinson's disease. J Pharmacokinet Pharmacodyn 32 (2005) 307-331
11. Chang W.Y., and Webster R.A. Effect of l-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats. Br J Pharmacol 121 (1997) 331-337
12. * by multiple gradient recaled echo functional MRI. Magn Reson Imaging 14 (1996) 469-476
13. Chihara K., Kashio Y., Kita T., Okimura Y., Kaji H., Abe H., et al. l-Dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 62 (1986) 466-473
14. Contin M., Martinelli P., Riva R., Dondi M., Fanti S., Pettinato C., et al. Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT. J Neurol 250 (2003) 1475-1481
15. Contin M., Riva R., Martinelli P., Albani F., Avoni P., and Baruzzi A. Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther Drug Monit 23 (2001) 621-629
16. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., and Baruzzi A. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 44 (1994) 1287-1292
17. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., and Baruzzi A. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 53 (1998) 1374-1375
18. Cotzias G.C., van Woert H.H., and Schiffer L.M. Aromatic amino acids and modifications of parkinsonism. New Engl J Med 276 (1967) 374-379
19. Folstein M.F., and Luria R. Reliabiliy, validity, and clinical application of the visual analogue mood scale. Psychol Med 3 (1973) 479-486
20. Goldstein D.S., Stull R., Markey S.P., Marks E.S., and Keiser H.R. Dihydrocaffeic acid: a common contaminant in the liquid chromatographic-electrochemical measurement of plasma catecholamines in man. J Chromatogr 311 (1984) 148-153
21. Hardie R.J., Malcolm S.L., Lees A.J., Stern G.M., and Allen J.G. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22 (1986) 429-436
22. Hershey T., Black K.J., Stambuk M.K., Carl J.L., McGee-Minnich L.A., and Perlmutter J.S. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 95 (1998) 12016-12021
23. Hershey T., Black K.J., Carl J.L., and Perlmutter J.S. Dopa-induced blood flow responses in non-human primates. Exp Neurol 166 (2000) 342-349
24. Hershey T., Black K.J., Carl J.L., McGee-Minnich L.A., Snyder A.Z., and Perlmutter J.S. Chronic treatment and disease severity alter brain responses to levodopa in PD. J Neurol Neurosurg Psychiatry 74 (2003) 844-851
25. Hornykiewicz O. Die Topische Lokalisation und das Verhalten von Noradrenalin und Dopamin in der Substantia Nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75 (1963) 309-312
26. Hornykiewicz O., and Birkmayer W. Biochemisch-pharmakologische Grundlagen für die klinische Anwendung von l-dioxyphenylalanin beim Parkinson-Syndrom. Wien Klin Wochenschr 73 (1961) 839-840
27. Huotari M., Gainetdinov R., and Mannistro P.T. Microdialysis studies on the action of tolcapone pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol Toxicol 85 (1999) 233-238
28. Karimi M., Carl J.L., Loftin S., and Perlmutter J.S. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. J Chromatogr B Biomed Sci Appl 836 (2006) 120-123
29. Kimura Y., Kihira K., Miyake K., Kitaura T., and Fukuchi H. Effects of l-dopa on cholecystokinin octapeptide tissue levels in normal and 6-hydroxydopamine-treated rat brain. Biol Pharmacol Bull 18 (1995) 13-17
30. Kobari M., Fukuuchi Y., Shinohara T., Obara K., and Nogawa S. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders. J Neurol Sci 128 (1995) 212-218
31. Lin T., and Tucci J.R. Provocative tests of growth-hormone release. A comparison of results with seven stimuli. Ann Intern Med 80 (1974) 464-469
32. Loche S., Balzano S., Bozzola M., Moretta A., Pintus S., Faedda A., et al. Secretion of growth hormone releasing hormone in obese children. J Endocrinol Invest 15 (1992) 453-457
33. Melamed E., Globus M., Friedlender E., and Rosenthal J. Chronic l-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections. Neurology 33 (1983) 950-953
34. Miller P.R., Dasher R., Collins R., Griffiths P., and Brown F. Inpatient diagnostic assessments. 1. Accuracy of structured versus unstructured interviews. Psychiatry Res 105 (2001) 255-264
35. Newman R.P., Weingartner H., Smallberg S.A., and Calne D.B. Effortful and automatic memory: effects of dopamine. Neurology 34 (1984) 807
36. Nutt J.G., and Woodward W.R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36 (1986) 739-744
37. Nutt J.G., Woodward W.R., and Anderson J.L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 18 (1985) 537-543
38. Nutt J.G., Carter J.H., Lea E.S., and Woodward W.R. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 12 (1997) 285-292
39. Orosz D., and Bennett J.P. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat. Exp Neurol 115 (1992) 388-393
40. Papavasiliou P.S., Cotzias G.C., Duby S.E., Steck A.J., Fehling C., and Bell M.A. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. New Engl J Med 286 (1972) 8-14
41. Petraglia F., De Leo V., Sardelli S., Mazzullo G., Gioffre W.R., Genazzani A.R., et al. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest 23 (1987) 103-109
42. Pontiroli A.E., Castegnaro E., Vettaro M.P., Viberti G.C., and Pozza G. Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine. Acta Endocrinol (Copenh) 84 (1977) 36-44
43. Porrino L.J., Burns R.S., Crane A.M., Palombo E., Kopin I.J., and Sokoloff L. Local cerebral metabolic effects of l-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Proc Natl Acad Sci USA 84 (1987) 5995-5999
44. Rau K.S., Buchholz J., Iacono R.P., Kirby M., and Maeda G. Blocking serotonin reuptake reduces exogenous l-DOPA derived dopamine release in chemically dopamine-depleted rats. Soc Neurosci Abstr (2002) 28 Program no. 292.13
45. Robertson D.R.C., Wood N.D., Everest H., Monks K., Waller D.G., Renwick A.G., et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28 (1989) 61-69
46. Roe D.L. From DOPA to Parkinson's disease: the early history of dopamine research. J Hist Neurosci 6 (1997) 291-301
47. Steiner J.L., Tebes J.K., Sledge W., and Walker M.L. A comparison of the structured clinical interview for DSM-III-R and clinical diagnoses. J Nerv Ment Dis 183 (1995) 365-369
48. 11C] raclopride displacement and PET. Neurology 46 (1996) 1430-1436
49. Trugman J.M. D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 795-810
50. Wade L.A., and Katzman R. Rat brain regional uptake and decarboxylation of l-DOPA following carotid injection. Am J Physiol 228 (1975) 352-359